Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Journal of Clinical Oncology

Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

Annals of Oncology

Overall survival with abemaciclib in early breast cancer

JAMA Oncology

Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer

Frontiers in Oncology

Cryoablation in the treatment of early breast cancer: A comprehensive analysis

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status